Source: Cancer Letters. Unidade: FM
Subjects: METÁSTASE NEOPLÁSICA, MELANOMA ANIMAL, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AGUIAR, Rodrigo Barbosa de et al. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Letters, v. 371, n. 2, p. 151–160, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.canlet.2015.11.030. Acesso em: 31 out. 2024.APA
Aguiar, R. B. de, Parise, C. B., Souza, C. R. T., Braggion, C., Quintilio, W., Moro, A. M., et al. (2016). Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Letters, 371( 2), 151–160. doi:10.1016/j.canlet.2015.11.030NLM
Aguiar RB de, Parise CB, Souza CRT, Braggion C, Quintilio W, Moro AM, Marques FLN, Buchpiguel CA, Chammas R, Moraes JZ de. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings [Internet]. Cancer Letters. 2016 ; 371( 2): 151–160.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/j.canlet.2015.11.030Vancouver
Aguiar RB de, Parise CB, Souza CRT, Braggion C, Quintilio W, Moro AM, Marques FLN, Buchpiguel CA, Chammas R, Moraes JZ de. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings [Internet]. Cancer Letters. 2016 ; 371( 2): 151–160.[citado 2024 out. 31 ] Available from: https://doi.org/10.1016/j.canlet.2015.11.030
